Aclarion Receives Pinnacle Award for AI Innovation
MWN-AI** Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in chronic low back pain solutions, recently earned a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category. This prestigious accolade underscores the efficacy of Aclarion's Nociscan platform, which utilizes Magnetic Resonance Spectroscopy (MRS) to assess chemical biomarkers in disc tissues, helping physicians pinpoint sources of chronic low back pain (cLBP). The recognition builds on Aclarion's earlier success at the 2025 Digital Health Awards, affirming the transformative potential of Nociscan in evaluating discogenic pain.
Chronic low back pain affects approximately 266 million individuals globally, presenting a significant healthcare challenge. Aclarion’s technology addresses this issue by offering objective, noninvasive insights into the pain-causing mechanics of intervertebral discs. The company’s cloud-based analytics platform processes MRS data, facilitating rapid deployment across different healthcare settings without the need for new hardware. This ability allows spine specialists to integrate advanced diagnostic insights into their treatment planning alongside existing clinical evaluations.
CEO Brent Ness highlighted the awards as validation of Aclarion's commitment to improving patient outcomes in a complex medical landscape. Nociscan not only delivers biochemical data that aids in treatment decisions but also boasts a remarkable surgical success rate of 97% when applied to identified painful discs.
With growing adoption among specialists seeking more reliable evaluation tools for cLBP, Aclarion aims to reshape the management of this prevalent condition. Through leveraging augmented intelligence and robust biomarker analysis, Aclarion is positioning itself at the forefront of MedTech innovation while aiming to significantly alleviate the burdens associated with chronic low back pain.
MWN-AI** Analysis
Aclarion, Inc. (Nasdaq: ACON, ACONW) has recently garnered significant recognition with its award-winning Nociscan technology for chronic low back pain, winning both the Diamond Pinnacle Award for AI Innovation and the 2025 Digital Health Award at HLTH. These accolades not only validate the company's innovative approach to addressing one of healthcare's most pressing issues but also highlight its potential in a vast and cost-intensive market.
The chronic low back pain (cLBP) market is a massive opportunity, with approximately 266 million individuals affected worldwide. Aclarion’s Nociscan employs magnetic resonance spectroscopy (MRS) to provide objective data on disc pain, enabling physicians to make informed decisions about treatment. The 97% surgical success rate associated with properly identifying painful discs positions Aclarion to disrupt traditional methods of cLBP diagnosis and treatment.
Given Aclarion's awards and significance in the cLBP market, investors should consider the following strategic insights:
1. **Growth Potential**: Aclarion is steering towards a lucrative market with a growing demand for objective diagnostic tools. Investing in Aclarion may provide exposure to the expansive digital health sector.
2. **Technological Edge**: The ability to leverage cloud-based algorithms allows for scalable implementation of Nociscan across various healthcare facilities, reducing barriers to entry in new markets.
3. **Clinical Validation**: The recognition and validation from prestigious award bodies enhance the company’s credibility, increasing potential partnerships and sales in a competitive landscape.
4. **Market Risks**: Potential risks include the highly regulated nature of healthcare technology and competition from alternative diagnostic methods. Investors should monitor these elements in their decision-making processes.
In summary, Aclarion represents an intriguing opportunity within the healthcare technology space, driven by innovation and significant market potential. However, careful consideration of market dynamics and risks is essential for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Recognition Follows 2025 HLTH Digital Health Award for Nociscan
Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market
BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has been awarded a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category. The award recognizes the company’s use of AI in its Nociscan solution for chronic low back pain, one of healthcare’s most pervasive and costly challenges.
This recognition follows Aclarion’s earlier selection as a 2025 Digital Health Awards at HLTH winner, where Nociscan was honored for its potential to transform the evaluation and management of discogenic low back pain. Together, the Pinnacle and HLTH awards reflect growing external validation of Aclarion’s mission to bring objective, MR spectroscopy?based biomarker analysis into routine clinical decision?making while advancing a new model of MedTech innovation built on scalable, cloud-based algorithms.
“Receiving recognition from both the Pinnacle Awards and HLTH underscores the accelerating momentum behind our technology,” said Brent Ness, CEO of Aclarion. “Chronic low back pain remains one of the most challenging and costly conditions in medicine. Providing physicians with objective biochemical data has the potential to fundamentally improve how discogenic pain is evaluated and treated.”
Aclarion’s flagship platform, Nociscan, uses MR spectroscopy to identify chemical biomarkers within intervertebral discs. These biomarkers are processed through proprietary algorithms that classify whether a disc’s biochemical profile is consistent with a painful or non?painful disc. Physicians use this information—alongside imaging, clinical evaluation, and their own expertise—to optimize treatment planning for patients with discogenic low back pain.
The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain. Since Nociscan is delivered through a cloud-based analytics platform, it can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used alongside other diagnostic tools, clinical data demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ**
How does Aclarion Inc. ACON plan to leverage the recognition from the HLTH Digital Health Award to expand its market presence in the chronic low back pain sector?
What specific advantages does Aclarion Inc. ACON believe its Nociscan technology offers compared to traditional methods for diagnosing discogenic low back pain?
Can Aclarion Inc. ACON share insights on the expected timeline for further clinical trials and regulatory approvals to expand Nociscan's adoption among healthcare providers?
In light of the recognized potential of Nociscan, how does Aclarion Inc. ACON intend to scale its cloud-based analytics platform to meet the growing demand from imaging centers and health systems?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. (NASDAQ: ACON).
NASDAQ: ACON
ACON Trading
-4.06% G/L:
$3.425 Last:
49,457 Volume:
$3.49 Open:
